$271 Million is the total value of JOHNSON & JOHNSON's 24 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporationads | $54,715,742 | -2.7% | 814,586 | 0.0% | 20.16% | +15.4% | |
| CVRX | CVRx, Inc. | $53,027,873 | -1.7% | 3,495,575 | 0.0% | 19.53% | +16.6% | |
| PTGX | Protagonist Therapeutics Inc. | $40,852,372 | -39.6% | 2,449,183 | 0.0% | 15.05% | -28.4% | |
| MGTX | MeiraGTx Holdings plc | $32,607,624 | -26.9% | 6,641,064 | 0.0% | 12.01% | -13.3% | |
| XNCR | Xencor, Inc. | $15,073,449 | -19.3% | 748,062 | 0.0% | 5.55% | -4.3% | |
| New | Neumora Therapeutics, Inc. | $12,870,126 | – | 912,128 | +100.0% | 4.74% | – | |
| Procept BioRobotics Corporation | $11,743,979 | -7.2% | 357,939 | 0.0% | 4.33% | +10.1% | ||
| FUSN | Fusion Pharmaceuticals Inc. | $9,543,342 | -44.3% | 3,670,516 | 0.0% | 3.52% | -34.0% | |
| NBTX | New | Nanobiotix S.A.sponsored ads | $8,396,824 | – | 959,637 | +100.0% | 3.09% | – |
| FATE | Fate Therapeutics, Inc. | $7,163,616 | -55.5% | 3,379,064 | 0.0% | 2.64% | -47.2% | |
| PNT | Point Biopharma Global Inc. | $6,670,000 | -26.4% | 1,000,000 | 0.0% | 2.46% | -12.7% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $6,652,958 | -24.6% | 247,598 | 0.0% | 2.45% | -10.6% | |
| ALDX | Aldeyra Therapeutics, Inc. | $2,637,491 | -20.4% | 394,834 | 0.0% | 0.97% | -5.5% | |
| Cue Health, Inc. | $2,454,263 | +19.9% | 5,548,864 | 0.0% | 0.90% | +42.1% | ||
| VOR | Vor Biopharma, Inc. | $2,278,275 | -31.4% | 1,074,658 | 0.0% | 0.84% | -18.6% | |
| NNOX | Nano-X Imaging Ltd. | $2,084,138 | -57.7% | 317,704 | 0.0% | 0.77% | -49.7% | |
| ACET | Adicet Bio, Inc. | $998,653 | -43.6% | 728,944 | 0.0% | 0.37% | -33.1% | |
| PHGE | BiomX Inc. | $750,958 | -2.2% | 2,133,402 | 0.0% | 0.28% | +16.4% | |
| SomaLogic, Inc. | $671,714 | +3.5% | 281,052 | 0.0% | 0.25% | +22.3% | ||
| CLSD | Clearside Biomedical, Inc. | $147,560 | -22.3% | 169,629 | 0.0% | 0.05% | -8.5% | |
| Apollomics, Inc. | $49,629 | -34.6% | 13,252 | 0.0% | 0.02% | -25.0% | ||
| CBIO | Catalyst Biosciences, Inc. | $32,290 | +37.2% | 66,951 | 0.0% | 0.01% | +71.4% | |
| SENS | Senseonics Holdings, Inc. | $32,986 | -20.9% | 54,621 | 0.0% | 0.01% | -7.7% | |
| TCON | Tracon Pharmaceuticals, Inc. | $14,953 | -38.8% | 84,003 | 0.0% | 0.01% | -25.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.